Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cobblestone Capital Advisors LLC NY

Cobblestone Capital Advisors LLC NY boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 300 shares of the biopharmaceutical company’s stock after acquiring an additional 75 shares during the period. Cobblestone Capital Advisors LLC NY’s holdings in Regeneron Pharmaceuticals were worth $315,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. raised its stake in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the last quarter. Team Hewins LLC grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares in the last quarter. Angeles Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the first quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares in the last quarter. TrinityPoint Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 12 shares during the last quarter. Finally, Western Financial Corp CA lifted its stake in shares of Regeneron Pharmaceuticals by 0.7% during the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after buying an additional 12 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 1.7 %

NASDAQ REGN opened at $1,131.50 on Friday. The stock has a market cap of $124.68 billion, a P/E ratio of 33.43, a PEG ratio of 3.13 and a beta of 0.12. The company’s fifty day simple moving average is $1,113.10 and its 200-day simple moving average is $1,020.18. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.79 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The disclosure for this sale can be found here. Insiders sold a total of 20,625 shares of company stock worth $22,298,963 in the last 90 days. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price for the company. Truist Financial reissued a “buy” rating and issued a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday. Finally, Argus raised their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,108.95.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.